Effekten af GCP-direktivet pa forskerinitierede kliniske laegemiddelforsog--sekundaerpublikation

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

  • L. Berendt
  • C. Hakansson
  • K.F. Bach
  • Dalhoff, Kim
  • P.B. Andreasen
  • L.G. Petersen
  • E. Andersen
  • H.E. Poulsen
Since 2004, adherence to Good Clinical Practice has been mandatory for all clinical drug trials. This was new to the investigator-initiated trials. Our study showed no association between the implementation of the Directive and investigator or industry-initiated trials. However, a steady decline was observed over the entire period. Presumably, the introduction of GCP did not entail a decline because of the presence of GCP units at university hospitals. Thus, researchers can conduct clinical drug trials under the same regulations as drug companies
Udgivelsesdato: 2008/8/11
OriginalsprogDansk
TidsskriftUgeskrift for læger
Vol/bind170
Udgave nummer33
Sider (fra-til)2437-2439
Antal sider2
ISSN0041-5782
StatusUdgivet - 2008

ID: 10912853